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A B S T R A C T

Background
Severe sepsis and septic shock are leading causes of death in the intensive care unit (ICU), despite advances in the treatment of patients with severe sepsis and septic shock, including early recognition, appropriate treatment with antibiotics and support of organs that may have been affected by the illness. High-volume haemofiltration (HVHF) is a blood purification technique that may improve outcomes in severe sepsis or septic shock. The technique of HVHF has evolved from renal replacement therapies used in the ICU to treat critically ill patients with acute kidney injury (AKI). This review was first published in 2013 and was updated in 2016.
Objectives
To investigate whether HVHF improves outcomes in critically ill adults admitted to the intensive care unit with severe sepsis or septic shock. The primary outcome of this systematic review is patient mortality; secondary outcomes include duration of stay, severity of organ dysfunction and adverse events.
Search methods
For this updated version, we extended searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Latin American Caribbean Health Sciences Literature (LILACS), Web of Science and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) to 31 December 2015. The original search was performed in 2011. We also searched trials registers.
Selection criteria
We included randomized controlled trials (RCTs) and quasi-randomized trials comparing HVHF or high-volume haemodiafiltration versus standard or usual dialysis therapy, as well as RCTs and quasi-randomized trials comparing HVHF or high-volume haemodiafiltration versus no similar dialysis therapy. These studies involved adults treated in critical care units.
Data collection and analysis
Three review authors independently extracted data and assessed trial quality. We sought additional information from trialists as required.
Main results
We included four randomized trials involving 200 participants. Owing to small numbers of studies and participants, it was not possible to combine data for all outcomes. Two trials reported 28-day mortality, and one trial reported hospital mortality; in the third trial, the number of deaths stated did not match the quoted mortality rates. The pooled risk ratio (95% confidence interval) for 28-day mortality associated with HVHF was 0.89 (0.60 to 1.32, two trials, 146 participants, low-quality evidence). One study (137 participants, lowquality evidence) reported length of stay in the ICU. Two trials (170 participants, low-quality evidence) reported organ dysfunction, but we could not pool results owing to reporting differences. Three studies (189 participants, low-quality evidence) reported on haemodynamic changes, but we could not pool results owing to reporting differences. Investigators reported no adverse events. Overall, the included studies had low risk of bias.
Authors' conclusions
Investigators reported no adverse effects of HVHF (low-quality evidence). The results of this meta-analysis show that very few studies have been conducted to investigate the use of HVHF in critically ill patients with severe sepsis or septic shock (four studies, 201 participants, low-quality evidence). Researchers should consider additional randomized controlled trials that are large and multi-centred and have clinically relevant outcome measures. The cost-effectiveness of HVHF should also be studied. .
P L A I N L A N G U A G E S U M M A R Y
High-volume haemofiltration for sepsis
Background Severe sepsis and septic shock are among the most common causes of death in adults admitted to an intensive care unit (ICU). Sepsis often arises after infection, when the body responds by producing chemicals that cause massive inflammation throughout the body. This inflammation can cause organs such as kidneys, heart, circulation or lungs to fail. It is these organ failures, which result from inflammation, that lead to the high death rates associated with sepsis.
Theoretically, if it were possible to artificially neutralize or remove these chemicals from the bloodstream, patient outcomes (such as organ failure and death) might improve. High-volume haemofiltration (HVHF) is one method that could be used. Standard haemofiltration is a treatment already used in the ICU to remove toxins that build up when a patient's kidneys have stopped working. This treatment involves removal of blood from the patient via a large catheter (a hollow, flexible tube placed into a large vein). After the blood has been removed, it is passed through a filter that removes toxins. The 'purified' blood is then returned to the patient via the catheter. HVHF, a more intense form of this treatment, aims to remove even more toxins (including some of the toxic chemicals produced during sepsis). However, HVHF presents potential disadvantages. This specialized technique requires specific equipment and extra training. Theoretically, it could have harmful effects on a patient's blood pressure or could remove beneficial chemicals (such as antibiotics). For this review, we assessed whether high-volume haemofiltration improves outcomes such as risk of death among patients with severe sepsis.
Study characteristics
This review is current until December 2015. We included four trials involving 205 participants. All four studies assessed effects of HVHF compared with the current standard haemofiltration and included participants with severe sepsis or septic shock who had been admitted to an ICU. Three of the four studies were very small (fewer than 20 participants enrolled in each study). The maximum time that participants were followed up after inclusion in any of the studies was 28 days. Two studies received financial support from pharmaceutical companies, and one study received support from a health research organization.
Key results
Outcome data were limited -two trials reported death rates at 28 days and one reported death rates in hospital; in the fourth study, the number of deaths stated did not match the quoted mortality rates. One study reported length of stay in the ICU, and one provided data on organ dysfunction. Investigators described no complications.
No clear evidence showed any benefit of HVHF in critically ill patients with severe sepsis or septic shock.
Quality of evidence
Evidence is insufficient to support the routine use of high-volume haemofiltration in patients with severe sepsis or septic shock. Studies included in this review reported relatively small numbers of participants and measured different outcomes; therefore, we judged the quality of evidence with respect to the impact of HVHF as low. Larger trials, carried out at many centres, are required for full assessment of clinically relevant outcomes and for evaluation of cost versus benefit.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Should high-volume haemofiltration vs standard or usual dialysis be used for sepsis? 
B A C K G R O U N D
Description of the condition
Sepsis is the body's response to infection. Sepsis is 'severe' when infection leads to organ dysfunction or failure. Septic shock is present when infection causes acute circulatory failure that leads to persistent hypotension despite adequate fluid resuscitation. Severe sepsis and septic shock are leading causes of the multiple organ dysfunction syndrome, as well as death, in the intensive care unit (ICU). Associated mortality remains very high, ranging from 30% to 50% (Surviving Sepsis Campaign 2008) despite advances in the treatment of patients with severe sepsis and septic shock, including early recognition, source control, timely and appropriate administration of antimicrobial agents and goal-directed haemodynamic, ventilatory and metabolic therapies (Alejandria 2010; Annane 2004; Gomes Silva 2010; Martí-Carvajal 2011). The number of patients with severe sepsis and septic shock continues to grow and is estimated to increase in the United States (USA) by a rate of 1.5% per year. To the current annual incidence of 3.0 cases per 1000 of the population, this would add an additional one million cases per year in the USA alone by 2020 (Angus 2001) . This increase is thought to be due to rising numbers of elderly and high-risk patients in the population and growing use of invasive procedures within hospital settings (Surviving Sepsis Campaign 2008). Our understanding of the complex pathophysiology of sepsis is evolving. The sepsis syndrome is no longer seen just as a disorder of uncontrolled inflammation; it is regarded more as a syndrome reflecting loss of balance between pro-inflammatory and anti-inflammatory mediators (Hotchkiss 2003) resulting in organ damage and development of the multiple organ dysfunction syndrome with its associated high mortality. The sepsis syndrome can occur with or without acute kidney injury (AKI; formerly known as acute renal failure (ARF)). It was once thought that immunological events in sepsis lead to elevated levels and activity of inflammatory mediators, and that the resulting cascade attempts to restore immunological homeostasis (Adrie 2000). Attempts were made to halt this 'inflammatory cascade' by blocking or antagonizing single inflammatory mediators. This did not lead to improvement in outcomes for patients with sepsis/septic shock (Abraham 2000) . It is increasingly recognized that the systemic inflammatory reaction that characterizes sepsis involves very complex interactions between endothelial cells, platelets, leucocytes, the coagulation system and multiple inflammatory mediators (Joannidis 2009). It would appear that the initial concept of sepsis as a stepwise progression down an inflammatory cascade of mediator release is an oversimplification. In addition to the pro-inflammatory systemic inflammatory response syndrome (SIRS) reaction (marked by overproduction of mediators such as interleukin-1, interleukin-6, interleukin-8 and tumour necrosis factor-α), sepsis comprises a 'hyporesponsive' component. This excessive anti-inflammatory counterpart to sepsis is referred to as the 'compensated anti-inflammatory response syndrome' (CARS) (Ronco 2003) . The SIRS and CARS components may happen in sequence (as in 'the sequential or serial sepsis theory'), with proinflammatory and anti-inflammatory mediators alternatively produced during high-generation or low-generation periods, leading to SIRS or CARS, or both. Alternatively, SIRS and CARS may occur simultaneously (as described in 'the parallel sepsis theory') (Ronco 2003) . Managing these excessive inflammatory and counter inflammatory responses while restoring balance to the immune system is an important therapeutic goal in the management of severe sepsis/ septic shock.
Description of the intervention
Continuous haemofiltration has been used for some time to treat critically ill patients with AKI who require renal replacement therapy. This blood purification technique involves removing water and solutes from the patient's blood by convection by applying positive hydrostatic pressure across a filter membrane. In contrast, haemodialysis utilizes the process of diffusion. The fluid removed during haemofiltration, which contains water and solutes, is known as 'ultrafiltrate'. The volume of ultrafiltrate removed during the process of continuous haemofiltration can vary depending on how the clinician prescribes treatment. The amount of ultrafiltrate removed by this treatment is described in millilitres (mL) of fluid per kilogram (kg) of the patient's body weight per hour (i.e. mL/kg/h). The 'standard' ultrafiltrate volume removed can be considered between 25 and 35 mL/kg/h. In 'high-volume' haemofiltration, the ultrafiltration volume is greater than 35 mL/ kg/h (Ronco 2000).
How the intervention might work
Pro-inflammatory and anti-inflammatory mediators involved in the sepsis syndrome can be found in the ultrafiltrate of patients who have received continuous haemofiltration (De Vriese 1999). It has been suggested that potential clinical benefit may result from the non-specific reduction in peak concentrations of these mediators (Ronco 2001) that is achieved by increasing the volume of ultrafiltrate removed to levels above those used to treat patients with AKI.
Why it is important to do this review
The technical requirements of high-volume haemofiltration (HVHF), including tightly controlled blood flow and ultrafiltration rates, good central venous vascular access, continuous anticoagulation and use of large amounts of sterile fluid, are both problematic and demanding for ICU staff. High-volume haemofiltra-tion may also be associated with increased, and unmeasured, removal of potentially beneficial substances such as medications or trace elements. The impact of these losses on patient outcomes is uncertain. In addition, considerable financial cost is associated with this procedure, and it is uncertain whether this relatively new technology offers clinically important benefit for patients with severe sepsis or septic shock (Reiter 2002).
O B J E C T I V E S
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomized controlled trials (RCTs) and quasi-randomized trials (trials in which the method of allocation is not truly random but could rely, for example, on allocation by date of birth) comparing HVHF or high-volume haemodiafiltration versus standard or usual dialysis therapy; and RCTs and quasi-randomized trials comparing HVHF or high-volume haemodiafiltration versus no similar dialysis therapy. We defined quasi-randomized trials as those involving a method of allocation to study groups that was not truly random (e.g. by alternating allocation to treatment or control groups on the basis of the order of inclusion into the study). We included only studies that clearly stated the dosage of highvolume ultrafiltration used. We excluded studies that did not report the primary outcome as detailed below. We did not include conference proceedings and meeting abstracts in this review.
Types of participants
We included studies of adults aged 16 years and older with severe sepsis or septic shock in an ICU setting. We accepted study authors' definitions of severe sepsis and septic shock. We included both patients with severe sepsis or septic shock and AKI and those with severe sepsis or septic shock but without AKI. We accepted study authors' definitions of AKI.
We excluded studies with participants younger than 16 years of age, those with participants without severe sepsis or septic shock and those not conducted in an ICU setting.
Types of interventions
High-volume haemofiltration (or haemodiafiltration) defined as haemofiltration (or haemodiafiltration) in which an ultrafiltration rate greater than 35 mL/kg/h was achieved. High-volume haemofiltration (or haemodiafiltration) was the experimental intervention. Participants in the control intervention group were those who received 'standard or usual' dialysis therapy (continuous or intermittent haemofiltration, haemodiafiltration or haemodialysis) and those who received no similar dialysis therapy. We accepted the study authors' definitions of pulse (if applicable) and continuous high-volume haemofiltration (or haemodiafiltration). 
Types of outcome measures
Searching other resources
When appropriate, we contacted the first authors of studies included in the review to obtain further information on unpublished studies or work in progress. We did not apply language or publication restrictions.
Data collection and analysis
Selection of studies
Two review authors (EMJB and KSR) independently assessed all titles and abstracts. We obtained full papers for studies that might have fulfilled the inclusion criteria. We (EMJB and KSR) independently assessed these studies to determine whether they fulfilled the inclusion criteria. When necessary, we planned to resolve disagreements by discussion and, if necessary, through the decision of a third review author (APM).
Data extraction and management
Two review authors (EMJB and CJH) independently extracted data using a modified version of the data extraction form of the Cochrane Anaesthesia, Critical and Emergency Care Group, as given in Appendix 7. We resolved disagreements by discussion and were not blinded with regard to the names of study authors, investigators or institutions, nor to study results. We listed excluded trials and reasons for exclusion. We piloted the data extraction form before use.
Assessment of risk of bias in included studies
Two review authors (EMJB, CJH) independently assessed risk of bias of included studies by addressing six specific domains (random sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting and other issues), as set forth in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We resolved disagreements by discussion and planned to involve a fourth review author (APM) should this be necessary. Each domain included specific entries in a 'Risk of bias' table. We assessed risk of bias as 'low', 'high' or 'unclear'. We contacted the first authors of included studies for further information on study design when we judged this to be necessary. We created plots of the risk of bias in RevMan 5.3.
Measures of treatment effect
We included and combined data using RevMan 5.3, when appropriate, by intervention, outcome and population.
For dichotomous data, we used risk ratios (RRs) with 95% confidence intervals (CIs).
For continuous data, we used, as appropriate, mean differences (MDs) with 95% CIs or standard mean differences (SMDs).
Unit of analysis issues
We had no unit of analysis issues.
Dealing with missing data
We contacted the original investigators to request missing data. We planned to make explicit assumptions about any methods used to cope with missing data, for example, that the data are assumed missing at random, or that missing values are assumed to have a particular value such as a poor outcome. This approach reflects the guidelines set forth in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).
Assessment of heterogeneity
We planned to test statistical heterogeneity by using the I 2 statistic. We planned to pool clinically and statistically homogeneous studies using the fixed-effect model. We planned to pool clinically homogeneous and statistically heterogeneous (I 2 statistic > 50%) studies using the random-effects model, if appropriate, as set forth in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011) . We planned to assess clinical heterogeneity by judgement and to attempt to calculate pooled summary effects only in the absence of clinical heterogeneity.
Assessment of reporting biases
If sufficient studies were identified, we planned to construct funnel plots (trial effect vs standard error) to assess possible publication bias.
Data synthesis
We combined data, when possible, using random-effects models and assessed heterogeneity using the I 2 statistic, as described above.
We reported the main outcomes of this review in Summary of findings for the main comparison. We incorporated the GRADE approach to interpret findings and used the GRADE profiler to import data from RevMan 5.3 to help to create Summary of findings for the main comparison. We included the following outcomes in Summary of findings for the main comparison. 1. ICU mortality. 2. 28-Day mortality.
3. Hospital mortality.
Subgroup analysis and investigation of heterogeneity
If adequate data were available, we planned to perform a priori subgroup analysis for the following categories. 1. Patients with severe sepsis or septic shock and AKI and those with severe sepsis or septic shock but without AKI.
2. Pulse HVHF and continuous HVHF. 3. Dosage of high-volume ultrafiltration used. 4. Type of ICU: surgical (including cardiac and trauma), medical or mixed (including all patient categories).
Sensitivity analysis
If appropriate, we planned to perform a sensitivity analysis to look at review results with and without studies that we deemed to have high risk of bias.
R E S U L T S
Description of studies
See Figure 1 . 
Results of the search
For our published review (Borthwick 2013), the combined search of MEDLINE, Embase, CINAHL and CENTRAL yielded 1282 potentially relevant studies. After reviewing titles and abstracts, we excluded 1253 studies. We retrieved the full-text versions of 29 studies, and we excluded 26 of these study reports. The major reason for exclusion was that identified studies were not randomized, or that participants were not appropriate. Examples of inappropriate participants included patients with pancreatitis, patients with AKI who were not all septic and patients with AKI plus nonrenal organ failure who were not necessarily septic. One study was published as an abstract (Zainudin 2006) and as a paper with a different first author (Ghani 2006) . We included the full paper. The updated search from August 2011 to December 2015 revealed 309 additional potentially relevant studies. We retrieved the fulltext versions of five studies. We excluded four of these studies as they were systematic reviews, provided inappropriate interventions or enrolled inappropriate participants. Finally, we included in the qualitative synthesis four studies (Boussekey 2008; Cole 2001; Ghani 2006; Joannes-Boyau 2013) published in five reports with a total of 200 participants. We reported in the Characteristics of included studies table the characteristics of populations and interventions described in the included trials. We contacted the first author of three studies (Boussekey 2008; Cole 2001; Ghani 2006) to ask for further information on the randomization process and the outcome measures described. All three study authors gave expanded details of the randomization process, and two study authors provided further information on and clarification of outcome measures. Joannes-Boyau 2013 provided sufficient information in the published material on the randomization process used in this study.
Included studies
Only four studies with 200 participants met the entry criteria for this updated systematic review (Boussekey 2008; Cole 2001; Ghani 2006; Joannes-Boyau 2013) . Boussekey 2008 was a single-centre randomized controlled trial that investigated vasopressor doses and other clinical outcomes, such as mortality, in 19 participants over a 28-day period following study inclusion. The mean age of participants was 68 years, and 78% were male. Investigators compared HVHF (65 mL/kg/h) versus control (35 mL/kg/h). Cole 2001 was a single-centre randomized cross-over trial that investigated haemodynamic changes and plasma concentrations of inflammatory mediators in 11 participants over a 48-hour period following study inclusion. The mean age of participants was 63.1 years, and 73% were male. Investigators compared HVHF (6000 mL/h for 8 hours) versus control (1000 mL/h for 8 hours). Ghani 2006 was a single-centre parallel randomized controlled trial that investigated haemodynamic status, inflammatory mediator concentrations and organ dysfunction scores in 33 participants. The mean age of participants was 58 years, and 53% were male. Investigators compared HVHF (6000 mL/h for 6 hours) versus control (2000 mL/h for 6 hours). Joannes-Boyau 2013 was a multi-centre randomized controlled trial that investigated 28-day mortality and other clinical outcomes in 137 participants. The mean age of participants was 68 years, and 68% were male. Investigators compared HVHF (70 mL/kg/ h for 96 hours) versus control (35 mL/kg/h for 96 hours). For full details, see Characteristics of included studies.
Excluded studies
We excluded 32 studies from the analysis. In one case, the outcome measurement -assessment of acid-base balance -was not appropriate (Cole 2003). One paper was an abstract for a paper published in full and already included (Zainudin 2006) .
Studies awaiting assessment
There are no studies awaiting classification.
Ongoing studies
We found no ongoing studies on HVHF.
Risk of bias in included studies
All included studies were randomized controlled trials; one had a cross-over design (Cole 2001) , and none were quasi-randomized clinical trials. Figure 2 shows the 'Risk of bias' summary, and Figure  3 the 'Risk of bias' graph.
Figure 2. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
Figure 3. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Allocation
All four included studies had low risk of selection bias in the random sequence generation domain. Two studies had low risk of bias in the allocation concealment domain. One study used sealed opaque envelopes (Cole 2001), and another used computer-generated randomized allocation (Joannes-Boyau 2013). One study had unclear risk of bias (insufficient information available as to the process of randomization) (Ghani 2006), and another had high risk of bias (the randomized group for the last participant in each block was known in advance) (Boussekey 2008).
Blinding
All four included studies had low risk of performance bias. For outcomes assessed in this review, it was unclear to whom the blinding referred, leading to unclear risk of detection bias in all four included studies.
Incomplete outcome data
One study had low risk of attrition bias (Cole 2001) , and in the other three studies, this was unclear.
Selective reporting
All four included studies had low risk of reporting bias.
Other potential sources of bias
We found the included studies to be at low risk for other potential sources of bias.
One study author provided a statement that he had no conflicts of interest (Boussekey 2008). Two studies reported that investigators received pharmaceutical company funding (Cole 2001; Ghani 2006) . Cole 2001 stated that this group received pharmaceutical funding for cytokine and complement measurements only. Ghani 2006 stated that research was supported by a pharmaceutical company grant, but review authors could not determine the extent of the company's involvement in the study by reviewing the manuscript. Joannes-Boyau 2013 stated that one study author received support from a health research organization.
Effects of interventions
See: Summary of findings for the main comparison Should high-volume haemofiltration vs standard or usual dialysis be used for sepsis?
Primary outcomes Mortality
Boussekey 2008 described ICU mortality of 33.3% (three out of nine participants) in the treatment intervention group and 60%
(six out of 10 participants) in the control intervention group (risk ratio (RR) 0.59, 95% CI 0.19 to 1.59). Investigators reported 28-day mortality of 33.3% (three out of nine participants) in the treatment intervention group and 50% (five out of 10 participants) in the control intervention group (RR 0.67, 95% CI 0.22 to 2.03). Joannes-Boyau 2013 described 28-day mortality of 37.9% (25 out of 66 participants) in the treatment intervention group and 40.8% (29 out of 71 participants) in the control intervention group. We pooled results from Boussekey 2008 and Joannes-Boyau 2013 using random-effects modelling and have presented these results in Figure 4 and in Summary of findings for the main comparison. The pooled estimate of risk ratio (RR) was 0.89 (95% CI 0.60 to 1.32, two studies, 156 participants). We classified the strength of this evidence as low, using the GRADE rating scheme (grade reduced owing to imprecision). One study (Cole 2001) reported only hospital mortality rates, stated as 54.5% (six out of 11 participants), and as this was a crossover study, between-group comparisons were not possible. The fourth study (Ghani 2006) reported a mortality rate of 76% (25 out of 33 participants). It was not clear if this referred to ICU, hospital or other (e.g. 28-day mortality). In addition, closer examination of the data published in this paper revealed that the number of deaths stated did not match the quoted mortality rates, nor was it reflected in the survival function curve. We have not been able to receive clarification from the study author on this; therefore, we have not included it in our analysis of mortality.
Secondary outcomes
Length of stay
One study (Joannes-Boyau 2013) investigated length of ICU stay; researchers reported no difference in the median number of ICUfree days (75 days in the intervention group and 74 in the control group).
Organ dysfunction
Investigators in two studies (Ghani 2006; Joannes-Boyau 2013) stated that they measured the sequential organ failure assessment score (SOFA score). Ghani 2006 measured SOFA scores at days zero, one and seven, and at ICU and hospital discharge. The SOFA scores were similar in treatment and control intervention groups at baseline and fell in both groups by day seven, with a statistically significant fall in the control intervention group (P = 0.048 in the treatment group and P = 0.006 in the control intervention group). Joannes-Boyau 2013 measured SOFA scores at days four and 28 and reported no difference between median SOFA scores in the intervention and control groups at either time point. Joannes-Boyau 2013 also reported the simplified acute physiology score II (SAPS II) at days four and 28 and revealed no significant difference at either time point. We downgraded the evidence to low quality owing to imprecision.
Haemodynamic change
HVHF did not appear to cause haemodynamic instability in these studies. In Ghani 2006, study authors stated that they observed no significant drop in systolic blood pressure (SBP), diastolic blood pressure (DBP) or mean arterial pressure (MAP) after treatment. Boussekey 2008 showed that HVHF was associated with a decrease in norepinephrine dose greater than 75% in 24 hours in eight out of nine participants in the treatment intervention group compared with four out of 10 participants in the control intervention group (RR 2.22, 95% CI 1.01 to 4.51). Similarly, Cole 2001 noted that the dose of norepinephrine required for maintenance of target MAP during treatment decreased more during HVHF than during continuous veno-venous haemofiltration (CVVH). This was a median dose reduction of 10.5 µg/min (interquartile range (IQR) 11.0) versus 1.0 µg/min (IQR 6.0), for a proportional decrease of 68% (IQR 28%) versus 7% (IQR 59%). Owing to differing reporting methods, we were unable to produce pooled estimates of effect. We downgraded this evidence to low quality owing to imprecision. No researchers specifically commented on risk of central venous catheter-related infection, risk of mechanical complications related to catheter placement (malpositioned lines, haematoma, pneumothorax) or risk of bleeding related to anticoagulation. Ghani 2006 stated, "there were no reported cases of excessive bleeding and adverse side-effects". Boussekey 2008 reported, "no adverse event associated with HVHF, like severe hypophosphataemia or hypokalaemia, was recorded" and Cole 2001 said, "no adverse events were noted". Joannes-Boyau 2013 described three serious adverse events but stated that investigators judged none of these to have been directly related to the study intervention.
D I S C U S S I O N
Severe sepsis and septic shock are associated with poor patient outcomes. High-volume haemofiltration (HVHF) has been theorised to confer potential benefit in this setting. This systematic review shows that, despite the potential benefits of HVHF, very few studies have been conducted to investigate its use in patients with severe sepsis or septic shock. The studies included in this analysis included only small numbers of participants and used clinically diverse case definitions, treatment strategies and outcome measures.
The clinical heterogeneity of the included studies resulted in difficulty in pooling estimates for major outcomes. The evidence presented in Summary of findings for the main comparison and Figure 4 incorporates data from only two studies (Boussekey 2008; Joannes-Boyau 2013) and therefore should be interpreted with caution. Joannes-Boyau 2013 stated that the trial was prematurely terminated because of slow recruitment and, therefore, did not enrol the anticipated number of participants required to achieve the desired 85% power. These limited data suggest that HVHF does not appear to confer improved mortality risk over standard therapy. Limited evidence also shows a trend towards reduced vasopressor requirements in patients treated with HVHF. Boussekey 2008 and Cole 2001 commented on this finding, but differing methods of reporting precluded the possibility of a pooled estimate. The review authors believe that this updated systematic review has highlighted the continued paucity of evidence in this field and the need for additional large-scale clinical trials to determine the effects of HVHF.
Summary of main results
We found very weak evidence to support the use of high-volume haemofiltration in critically ill patients with severe sepsis/septic shock to improve outcomes. We found no evidence to suggest that the treatment intervention was harmful.
Overall completeness and applicability of evidence
The evidence reported here is weak as a result of the limited number of trials identified with few participants. Therefore, one must interpret the results of this review with caution.
Quality of the evidence
Flaws in reporting of outcome results further reduced the data available for analysis. Clinical heterogeneity in terms of time points for assessing mortality rates meant that it was difficult to pool estimates for all primary outcomes. The small number of studies identified and, in particular, the single-centre nature of three of the included studies (Boussekey 2008; Cole 2001; Ghani 2006) meant that review authors had to downgrade the quality of evidence produced in this review to low (reduced by two levels for imprecision).
Potential biases in the review process
The only potential bias in the review process of which review authors are aware is that we were unable to receive a response from the authors of Ghani 2006; this could have biased some of the results pertaining to mortality. However, given that Ghani 2006 was a small single-centre study, it seems unlikely that the results of this review would have been significantly altered by its inclusion in the quantitative synthesis for mortality.
Agreements and disagreements with other studies or reviews
We are not aware of any similar studies or reviews meeting our inclusion and exclusion criteria.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
The evidence presented in this review, although of low quality, suggests that HVHF does not provide significant benefit in terms of reduction in mortality among critically ill patients with severe sepsis or septic shock.
Implications for research
As noted, the evidence presented in this review is of low quality owing to the relatively small numbers of participants studied, the single-centre nature of many studies and the heterogeneity of reporting of key outcomes. Future studies should be multi-centre in nature and sufficiently powered to address key outcomes such as mortality. These studies should adopt standard definitions for the critical outcomes measured. For example, researchers should reach consensus as to the time point for assessing mortality rates, such as by limiting studies to measuring 28-day mortality from time of randomization. This would also apply to secondary outcomes for which studies should adopt standard protocols, for example, for administration of vasopressor agents, which would allow data to be pooled across studies. The financial implications of providing HVHF, including those related to equipment and staffing costs, should be assessed in a cost-benefit analysis. The review authors are not aware of any new trials, either registered or ongoing, involving the use of HVHF for sepsis.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Boussekey 2008 MW Systemic Inflammatory Response Syndrome S10 TX Multiple Organ Failure S11 TX multiorgan failure S12
TX sepsis* or septic* or SIRS S13 S12 or S11 or S10 or S9 or S8 or S7 S14 S13 and S6 Appendix 6. ISI Web of Science search strategy #1 TS=(purification SAME therap*) or TS=(Blood SAME purificat*) or TS=(purificat* SAME therap*) or TS=(h?emofiltrat* or h? emodiafiltrat* or ultrafiltrat*) or TS=(HVHF or HVHF) or TS=(Volume SAME (ultrafiltrat* or h?emofiltrat*)) #2 TS=(sepsis* or septic* or SIRS) or TS=(Systemic Inflammatory Response Syndrome) or TS=(Multiple Organ Failure) or TS=(multi? organ SAME failure) #3 #2 AND #1 #4 TS=(random*) or TS=(clinical trial*) or TS=(controlled trial*) or TS=placebo #5 #4 AND #3 Type of study Can the study be described as randomized or quasi-randomized, i.e. method of allocation is known but study is not considered strictly randomized? 
